WF
REGN icon

Welch & Forbes’s Regeneron Pharmaceuticals REGN Stock Holding History

Welch & Forbes’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-471
Closed -$211K – 352
2017
Q3 		$211K Sell
471
-128
-21% -$60.9K 0.01% 318
2017
Q2 		$294K Buy
599
+55
+10% +$24.1K 0.01% 293
2017
Q1 		$211K Buy
+544
New +$202K 0.01% 330

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Welch & Forbes's REGN Position: Q4 2017 in Review

Welch & Forbes sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 471 shares — an estimated $211K sold.

Welch & Forbes first reported a position in REGN in Q1 2017 and held it in 3 quarters. The position peaked at $294K in Q2 2017. 638 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • Welch & Forbes reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Welch & Forbes sold 471 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $211K.
  • Welch & Forbes first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Welch & Forbes's Regeneron Pharmaceuticals position peaked at $294K in Q2 2017.
  • 638 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Welch & Forbes's 13F filing for Q4 2017, filed 26 Jan 2018.